Triggering Factors of Primary Care Costs in the Years Following Type 2 Diabetes Diagnosis in Mexico

Archives of Medical Research

Volumn 45, Issue 5, 2014, Pages 400-408

  Castro Ríos, Angélica ^a   Nevárez Sida, Armando ^b   Tiro Sánchez, María Teresa ^b   Wacher Rodarte, Niels ^c  

^a HOSPITAL DE PEDIATRÍA   (Mexico)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^c HOSPITAL DE ESPECIALIDADES   (Mexico)

Author keywords

Direct costs; Predictors; Primary care; Resource use; Type 2 diabetes

Indexed keywords

GLUCOSE; INSULIN; ORAL ANTIDIABETIC AGENT;

ADULT; AGE; ARTICLE; CONTROLLED STUDY; DRUG USE; DYSLIPIDEMIA; FEMALE; GENERAL PRACTITIONER; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEALTH CARE COST; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MEXICO; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OBSERVATIONAL STUDY; PREDICTION; PRIMARY MEDICAL CARE; PUBLIC HEALTH SERVICE; RESPIRATORY TRACT INFECTION; SECONDARY ANALYSIS; SEX DIFFERENCE;

DIRECT COSTS; PREDICTORS; PRIMARY CARE; RESOURCE USE; TYPE 2 DIABETES;

ADULT; DIABETES MELLITUS, TYPE 2; FEMALE; HEALTH CARE COSTS; HUMANS; LINEAR MODELS; MALE; MEXICO; MIDDLE AGED; MODELS, ECONOMIC; PRIMARY HEALTH CARE;

EID: 84904685874     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2014.05.002     Document Type: Article

References (43)

1. Shaw J.E., Sicree R.A., Zimmet P.Z. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010, 87:4-14.
2. Villalpando S., Rojas R., Shamah-Levy T., et al. Prevalence and distribution of type 2 diabetes mellitus in Mexican adult population. A probabilistic survey. Salud Publica Mex 2010, 52(Suppl 1):S19-S26.
3. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee.Clinical Practice Guidelines, Organization of Diabetes Care. Can J Diabetes 2013, 37:S20-S25.
4. [Norma Oficial Mexicana NOM-015-SSA2-1994, Para la prevención, tratamiento y control de la diabetes]. Spanish. Available at: http://www.salud.gob.mx/unidades/cdi/nom/m015ssa24.html.
5. [2010-2011 Activity Report and Program of Activities. Office of Planning and Monitoring], Instituto Mexicano del Seguro Social. Spanish. Available at: http://www.imss.gob.mx/SiteCollectionDocuments/migracion/instituto/informes/2011/Informe%20de%20Labores%202010-2011.pdf.
6. Directorate of Medical Services.[Continuous model of equipment for Family Medicine Units IMSS]. Instituto Mexicano del Seguro Social 2002. Spanish.
7. Consejo de Salubridad General de México. [Guía de Práctica Clínica Diagnóstico, metas de control ambulatorio y referencia oportuna de prediabetes y diabetes mellitus tipo 2 en adultos en el primer nivel de atención]. SS-093-08. Spanish. Available at: http://www.cenetec.salud.gob.mx/descargas/gpc/CatalogoMaestro/093_GPC_Diabmellitus2/SSA_093_08_GRR.pdf.
8. World Health Organization.Diabetes. Fact Sheet [serial on the Internet]. November 2009 312:Available from: http://www.who.int/mediacentre/factsheets/fs312/en/index.html.
9. Coordination of Institutional Risk Management. [Evaluation of risks included in the Administrative Programme of Institutional Risks 2007]. Instituto Mexicano del Seguro Social. Spanish. Available at: http://www.imss.gob.mx/estadisticas/financieras/evaluacion_PARI.html.
10. Brandle M., Zhou H., Smith B.R., et al. The direct medical cost of type 2 diabetes. Diabetes Care 2003, 26:2300-2304.
11. Waugh N., Scotland G., McNamee P., et al. Screening for type 2 diabetes: literature review and economic modelling. Health Technol Assess 2007, 11:1-125. iii-iv, ix-xi.
12. Eastman R.C., Javitt J.C., Herman W.H., et al. Model of Complications of NIDDM: I. Model construction and assumptions. Diabetes Care 1997, 20:725-773.
13. Sabag-Ruiz E., Álvarez-Félix A., Celiz-Zepeda S., et al. [Complicaciones crónicas en la diabetes mellitus. Prevalencia en una unidad de medicina familiar]. Rev Med Inst Mex Seguro Soc 2006, 44:415-421.
14. Currie C.J., Gale E.A., Poole C.D. Estimation of primary care treatment costs and treatment efficacy for people with type 1 and type 2 diabetes in the United Kingdom from 1997-2007. Diabet Med 2010, 27:938-948.
15. Garattini L., Tediosi F., Chiaffarino F., et al. Gruppo di Studio Rilevazione Economicadei Costie Risorsenel Diabete. The outpatient cost of diabetes care in italian diabetes centers. Value Health 2001, 4:251-257.
16. Bahia L.R., Araujo D.V., Schaan B.D., et al. The costs of type 2 diabetes mellitus outpatient care in the Brazilian public health system. Value Health 2011, 14:S137-S140.
17. Ringborg A., Martinell M., Stålhammar J., et al. Resource use and costs of type 2 diabetes in Sweden-estimates from population-based register data. Int J Clin Pract 2008, 62:708-716.
18. Rodríguez Bolaños Rde L., Reynales Shigematsu L.M., Jiménez Ruíz J.A., et al. [Direct costs of medical care for patients with type 2 diabetes mellitus in Mexico micro-costing analysis]. Spanish. Rev Panam Salud Publica 2010, 28:412-420.
19. Brown J.B., Nichols G.A., Glauber H.S., et al. Type 2 diabetes: incremental medical care costs during the first 8 years after diagnosis. Diabetes Care 1999, 22:1116-1124.
20. Jonsson P.M., Marké L.A., Nyström L., et al. Excess costs of medical care 1 and 8 years after diagnosis of diabetes: estimates from young and middle-aged incidence cohorts in Sweden. Diabetes Res Clin Pract 2000, 50:35-47.
21. Johnson J.A., Pohar S.L., Majumdar S.R. Health care use and costs in the decade after identification of type 1 and type 2 diabetes. Diabetes Care 2006, 29:2403-2408.
22. Trogdon J.G., Hylands T. Nationally representative medical costs of diabetes by time since diagnosis. Diabetes Care 2008, 31:2307-2311.
23. Ho Kim T., Hong Chun K., Jin Kim H., et al. Direct medical costs for patients with type 2 diabetes and related complications: a prospective cohort study based on the Korean National Diabetes Program. J Korean Med Sci 2012, 27:876-882.
24. Lin T., Chou P., Tsai S.T., et al. Predicting factors associated with costs of diabetic patients in Taiwan. Diabetes Res Clin Pract 2004, 63:119-125.
25. Gilmer T.P., O'Connor P.J., Rush W.A., et al. Predictors of health care costs in adults with diabetes. Diabetes Care 2005, 28:59-64.
26. Meinert C.L. Chap. 9 Sample size and power estimates. Clinical Trials: Design, Conduct and Analysis (Monographs in Epidemiology and Biostatistics;vol. 8) 1986, 85-89. Oxford University Press, New York. A.M. Lilienfeld (Ed.).
27. Castro-Ríos A., Reyes-Morales H., Pérez-Cuevas R. [An evaluation of a continuing medical education program for primary care services in the hypoglycemic agent's prescription in diabetes mellitus type. Sal Pub Mex 2008, 50(Suppl 4):S445-S452. [Spanish].
28. Drummond M.F., Sculpher M.J., Torrance G.W., et al. Methods for the Economic Evaluation of Health Care Programmes 2005, Oxford University Press, Oxford. Third edition.
29. Official Journal of the Federation, 14-06-2011;1st section, Organismos descentralizados y/o desconcentrados, Instituto Mexicano del Seguro Social, [Spanish]. Available from: http://dof.gob.mx/nota_detalle.php?codigo=5194979%26fecha=14/06/2011.
30. Vittinghoff E., Glidden D.V., Shiboski S.C., et al. Basic statistical methods (chapter 3). Regression Methods in Biostatistics: Linear, Logistic, Survival, and Repeated Measures Models 2005, 29-68. Springer, New York. M. Gail, K. Krickeberg, J. Samet, A. Tsiatis, W. Wong (Eds.).
31. Barber J., Thompson S. Multiple regression of cost data: use of generalised linear models. J Health Serv Res Policy 2004, 9:197-204.
32. Basu A., Rathouz P.J. Estimating marginal and incremental effects on health outcomes using flexible link and variance function models. Biostatistics 2005, 6:93-109.
33. Wirehn A.B., Andersson A., Ostgren C.J., et al. Age-specific direct health care costs attributable to diabetes in a Swedish population: a register-based analysis. Diabet Med 2008, 25:732-737.
34. Berzel A., Heller G.Z., Zucchini W. Estimating the number of visits to the doctor. Aust NZ J Stat 2006, 48:213-224.
35. vonLengerke T., Hagenmeyer E.G., Gothe H., et al. Excess health care costs of obesity in adults with diabetes mellitus: a claims data analysis. Exp Clin Endocrinol Diabetes 2010, 118:496-504.
36. Influence of body mass index on prescribing costs and potential cost savings of a weight management programme in primary care. J Health Serv Res Policy 2008, 13:158-166. Counterweight Project Team.
37. Dilla T., Valladares A., Nicolay C., et al. Healthcare costs associated with change in body mass index in patients with type 2 diabetes mellitus in Spain: the ECOBIM study. Appl Health Econ Health Policy 2012, 10:417-430.
38. Karjalainen J., Peltonen M., Vanhala M., et al. Leisure time physical activity in individuals with screen-detected type 2 diabetes compared to those with known type 2 diabetes. Diabetes Res Clin Pract 2008, 81:110-116.
39. Wagner E.H., Sandhu N., Newton K.M., et al. Effect of improved glycemic control on health care costs and utilization. JAMA 2001, 285:182-189.
40. Palomo L., Rubio C., Gérvas J. The comorbidity in primary care. Gac Sanit 2006, 20(Suppl 1):182-191. Spanish.
41. Tharkar S., Satyavani K., Viswanathan V. Cost of medical care among type 2 diabetic patients with a co-morbid condition-hypertension in India. Diabetes Res Clin Pract 2009, 83:263-267.
42. Costi M., Smith H., Reviriego J., et al. [Direct health care costs in patients with type 2 diabetes mellitus six months after starting insulin treatment in Spain: the INSTIGATE study]. Endocrinol Nutr 2011, 58:274-282. Spanish.
43. Plotnikoff R.C., Karunamuni N.D., Johnson J.A., et al. Health-related behaviours in adults with diabetes: associations with health care utilization and costs. Can J Public Health 2008, 99:227-231.